Navigation Links
Celling Biosciences Received CE Mark Approval for ART PRP and ART BMC Systems

With an aging global population and rising dangers of opioid addiction and complications, demand for platelet-rich plasma and bone marrow concentrate based treatments has been steadily rising in the United States. According to the Global Regenerative Medicine Market 2016-2020 report, the specialty of regenerative medicine is forecasted to grow at a CAGR of 20.7%. Hank Brown, Celling Biosciences Executive Vice President of Sales, stated, “The CE Mark approval allows the company to respond to the growing opportunity in international markets, particularly within Europe, so this achievement is an important milestone in the company’s sales history and a strategic step in the company’s continued growth.”

The ART PRP and ART BMC are class-leading, sterile-packaged disposable devices that are used to concentrate a sample of a patient’s blood or bone marrow into their subcomponents through centrifugation. The concentration process takes less than 30 minutes at point-of-care and is often done on an outpatient basis depending on the procedure being performed. As peer-reviewed and presented at the Tissue Engineering and Regenerative Medicine International Society Annual Meeting (Sept 2015, Boston, MA), the ART BMC and ART BMC Plus devices consistently recovers 90% of concentrated autologous stem and progenitor cells, platelets, and growth factors – performance that is unrivaled in the world.

Also, unique to Celling Biosciences, the ART BMC and ART PRP systems have an optional, proprietary integrated filter system which allows physicians to further concentrate the patient’s platelet-rich plasma (PRP) or platelet-poor plasma (PPP) without any additional sterile breaks. In vitro studies have shown the filter system’s ability to concentrate proteins like alpha-2-macroglobulin (A2M), interleukin 1 receptor antagonist protein (IRAP), and fibrinogen.

Physicians can utilize the components of their choice to treat various orthopedic applications, employing ART PRP or ART BMC devices on average once every 42 minutes in the United States. The Celling Biosciences international business development team believes this level of usage will more than quadruple in the next year now that the European market is open for the ART family of products.

Kevin Dunworth, Celling Biosciences Founder and CEO, commented, “As the only company on the market with a cell-centric approach to all of our product lines, the development and commercialization of our proprietary ART PRP and ART BMC systems have been years in the making. Today is a proud moment for our company as we expand into the European market.”

About Celling Biosciences:
As the innovative leader in regenerative medicine, Celling Biosciences collaborates with physicians and scientists to develop the most sophisticated technologies and techniques for maximizing the collection, concentration, and delivery of autologous blood and bone marrow aspirate.

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related medicine news :

1. Adept Sound Has Announced the Market Launch of Innovative New Noise Cancelling Silicone Ear Plugs
2. Celling Biosciences Announces New Location in Austin, Texas
3. ACEA Biosciences, Inc. to be featured in Upcoming Episode of Innovations with Ed Begley, Jr.
4. INDIGO Biosciences Now Offers PXR
5. Sharp Edge Labs and Creagen Biosciences Enter Drug Discovery Collaboration
6. Wayne State opens new $93 million biosciences center aimed at eliminating health disparities in Detroit
7. GD Biosciences Announces Availability of the PULs Cardiac Test in India as Part of International Expansion
8. Vortex Biosciences Announces Publication in Oncotarget That Demonstrates the Value of Combining CTCs and cfDNA in Assessing Cancer Patient Disease
9. Vortex Biosciences Selected as Finalist for 2017 SLAS Innovation Award
10. Pierian Biosciences Names Mark S. Gelder, MD as Chief Medical Officer
11. Vortex Biosciences Announces Publication in Nature Communications Describing the First Single Cell Western Blot for Circulating Tumor Cells
Post Your Comments:
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today announced that it will release third-quarter ... October 26, 2017, and will follow with a conference ... 9:00 a.m. Eastern Time. To participate on the call, ... ID is 94093362. ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
Breaking Medicine Technology: